GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
NCT ID: NCT04100135
Last Updated: 2024-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
7 participants
INTERVENTIONAL
2021-02-05
2024-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Arm
Device PFO closure with the GORE® CARDIOFORM Septal Occluder
Actual device PFO closure
Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
Thienopyridine (clopidogrel or prasugrel)
Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Control Arm
Sham device PFO closure (PFO not closed)
Thienopyridine (clopidogrel or prasugrel)
Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Sham device PFO closure
Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Actual device PFO closure
Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
Thienopyridine (clopidogrel or prasugrel)
Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Sham device PFO closure
Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is willing and capable of complying with the study protocol requirements, including the specified follow-up period, and can be contacted by telephone.
3. Subject signed an Informed Consent Form prior to study participation.
4. Subject's symptoms meet International Classification of Headache Disorders - 3 (ICHD-3) Diagnostic Criteria for migraine with or without aura.
5. Subject has at least one year of migraine symptom duration.
6. Subject had migraine onset younger than 50 years of age.
7. Subject has more than one migraine headache day per week on average by history - headache day defined as: headache that meets ICHD-3 criteria for migraine or probable migraine with or without aura and lasts at least four hours or administration of acute medication before four hours (regardless of clinical response to acute medication).
8. Subject has tried and failed at least two preventive medications at adequate dosage for an adequate duration, in the judgement of the study site neurologist, and be from two separate classifications of the following classes of drugs: antidepressants, antihypertensive, anticonvulsant, onabotulinumtoxin A, CGRP inhibitors or other treatments with at least one positive randomized placebo-controlled trial (See APPENDIX A).
9. Subject must exhibit stable dosage on their preventive migraine medication for at least two months prior to the screening visit and agree to continue preventive medication at current dosage throughout the duration of the study.
10. Female subjects are currently not pregnant, breastfeeding or lactating and not planning pregnancy during their participation in the study.
11. Female subjects capable of becoming pregnant agree to use birth control or abstinence during their participation in the study.
12. Presence of Patent Foramen Ovale (PFO), as determined initially by positive bubble study utilizing Transthoracic Echocardiography (TTE) or transesophageal echocardiography (TEE), demonstrating right-to-left shunting.
13. Subject is willing to complete daily electronic migraine headache log.
14. Subject is not planning surgery during their participation the study.
Exclusion Criteria
2. Subject has known organic issues which may cause headaches (e.g., temporo-mandibular joint, brain tumor, cervical spinal issues, known seizure disorder, etc.).
3. Subjects with hemicrania continua, post-traumatic headache, or other trigeminal autonomic cephalalgia secondary headache disorders.
4. Subject has known hypersensitivity or contraindication to thienopyridines.
5. Subject is currently taking a P2Y12 inhibitor (See APPENDIX B).
6. Subject has need for chronic oral anticoagulation therapy (e.g., atrial fibrillation, mechanical heart valve, etc.) (See APPENDIX B).
7. Subject has need for chronic antiplatelet therapy.
8. Subject has need for daily use of non-steroidal anti-inflammatory drugs (NSAIDs) (See APPENDIX B).
9. Subject has a history of thrombocytopenia within one year, or platelet count \<100,000 mm3 identified during the screening phase.
10. Subject has severe hepatic impairment with reduced synthetic function as documented by prolongation of PT/PTT or total bilirubin \> 3.0 mg/dL identified during the screening phase.
11. Subject has any history of stroke, TIA, or intracranial hemorrhage.
12. Subject has previously implanted pacemaker, IVC filter, PFO closure device, ASD closure device, left atrial appendage closure device OR any cardiac surgical or interventional history which, in the investigator's opinion, would preclude them from study participation.
13. Subject has documented right-to-left shunt source in addition to PFO, such as pulmonary arteriovenous malformation.
14. Subject used opioids, marijuana (medical or recreational) or butalbital-containing medications for acute migraine headache treatment four or more times per month on average within the past six months.
15. Subject abuses alcohol and/or drugs in the opinion of the Investigator.
16. Subject is unable to understand the study requirements or has a history of non-compliance with medical advice.
17. Subject has a history of clinically significant bleeding within six months of the screening visit, any active bleeding, or active peptic ulcer disease.
18. Subject has an uncontrolled arrhythmia or, if on therapy, within the past 90 days has evidence of arrhythmia control failure (e.g., supraventricular tachycardia while under rate control or atrial fibrillation while under rhythm control).
19. Subject has elevated pulmonary vascular resistance (PVR) which, in the opinion of the implanting physician, precludes safe defect closure.
20. Subject has uncontrolled systemic hypertension at the time of screening, in the opinion of the investigator.
21. In the opinion of the Investigator, patient has anatomic criteria identified during the screening evaluation and/or the screening echocardiogram that are unfavorable for successful placement of the GORE® CARDIOFORM Septal Occluder.
22. Subject has active infection at the time of screening that cannot be treated.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
W.L.Gore & Associates
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Sommer, MD
Role: PRINCIPAL_INVESTIGATOR
Columbia University
David Dodick, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Arizona
Phoenix, Arizona, United States
UCLA Health
Los Angeles, California, United States
Santa Barbara Cottage Hospital Research Institute
Santa Barbara, California, United States
South Denver Cardiology
Denver, Colorado, United States
Medical Center of the Rockies
Loveland, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Mercy One Iowa Heart Center
West Des Moines, Iowa, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan Hospital
Ann Arbor, Michigan, United States
University at Buffalo
Buffalo, New York, United States
SJH Cardiology Associates
Liverpool, New York, United States
Columbia University Medical Center
New York, New York, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Aurora St Luke's Medical Center
Milwaukee, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GSO 17-03
Identifier Type: -
Identifier Source: org_study_id